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expected extent for a medical condition and a pharmaceutical treatment, 
respectively; and the independent variables were types of medical condition  
or pharmaceutical treatment, types of information sources, frequency of past 
information search, health, extraversion, gender, and metropolitan statistical 
area. RESULTS: A total of 505 consumers yielded complete interviews, with  
a cooperation rate of 37.4%. On average, they were 57 years old, and 61% of them 
were female. Twenty percent of them had expectations of seeking information 
for a medical condition, and 14% for a pharmaceutical treatment. All regressions 
were significant (p<0.01). Health and gender were significant predictors  
for expected likelihood, and health and extraversion were significant predictors 
for expected extent (p<0.05). CONCLUSIONS: As perceived health status 
worsened, consumers were not only more likely to search for information, but 
also to a larger degree. Women were more likely to search for information, and 
those who were outgoing tended to perform information search to a larger 
degree.  
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OBJECTIVES: Although the potential benefits of pharmacogenomic (PG) testing 
may be readily evident, there are numerous concerns creating barriers to its 
implementation. The purpose of our study was to compare various stakeholder 
attitudes and concerns toward PG testing as identified from the literature. A sub-
aim was to understand issues with PG testing identified by underrepresented 
groups. METHODS: Using specific keywords, we conducted a systematic 
literature search of electronic databases including PubMed, IPA, CINAHL, and 
EMBASE. Articles that evaluated the attitudes and beliefs about PG testing were 
included. Concerns identified in the studies were categorized into themes 
(ancillary information-related, clinical, economical, educational, ethical/legal, 
medical mistrust, and operational), and summarized according to stakeholder 
group (patients, general public, providers, payers and others). RESULTS: Of 1483 
citations identified in the initial search, 38 studies that presented 41 perspectives 
met the inclusion criteria, employing methods of eliciting perceptions via 
surveys, focus groups and interviews. Overall, there were 15 studies focusing on 
providers, 9 on general public, 9 on patients, and 4 on payers, and 4 on other 
stakeholder perspectives. Studies of the general public most commonly 
identified issues related to medical mistrust (n=5), education (n=5) and 
operations (n=5). The most prevalent issues from the patient perspective 
included ethical/legal (n=6) and economical (n=5). Clinical (n=11) and educational 
(n=11) issues related to PG testing were recognized as frequent among the 
providers. Among the payer perspective, operational (n=4) and clinical (n=3) 
issues were prominent. In the underrepresented groups, concerns of medical 
mistrust and economical issues were notably higher compared to other groups. 
CONCLUSIONS: While the number of studies, assessing attitudes and concerns 
of various stakeholders, has increased over the last five years, the fundamental 
issues remain unchanged. Improved understanding of such issues may help 
strengthen the uptake of pharmacogenomic testing in clinical practice and lead 
to better health outcomes.  
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OBJECTIVES: To address questions about the importance of public (patients, 
patient groups, etc) engagement in HTA processes with the objective to – 1) 
explore ideas regarding the use of public engagement in decision making 
processes (specifically coverage decisions), and 2) contextualise some of  
the main arguments found by assessing the Canadian Agency for Drugs and 
Technologies in Health’s (CADTH) current public engagement mechanisms for  
its Common Drug Review (CDR). METHODS: A literature search was performed to 
identify key theoretical arguments for and against public engagement in HTA 
processes. The search was mainly focused on sources from Canada and the UK. 
A review of CADTH’s website was conducted for technology appraisals 
completed by the CDR process since the start of its public engagement initiatives 
(to mid-August 2012). RESULTS: Key arguments for public engagement in 
decision making include: transparency, accountability, equity, and creating a 
patient-centric health system. With the CDR, the percentage of appraisals 
conducted for coverage decisions that included public (patient group) input was 
48%. The lack of engagement from patient groups on half of the appraisals 
highlights some of the key challenges of public engagement (e.g., lack of 
awareness, lack of budget). Furthermore, the documents reviewed showed that 
some indications received more responses than others (e.g., epilepsy, 
schizophrenia). This may potentially result in some underfunded patient groups 
feeling disempowered, which is a risk of engagement. CONCLUSIONS:  
The findings of the study support initiatives that encourage the engagement  
of the public so that decision makers can better incorporate the values held  
by citizens. However, the relative value of doing so will vary. To ensure that 
public engagement in HTA is appropriate and fair, Canada and other 
jurisdictions must have political will, dedicated resources, and the motivation to 
facilitate educational activities that support active engagement from all types of 
public.  
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OBJECTIVES: To examine the impact of cost-sharing on the demand for 
medication across several classes of prescription medications indicated to treat 
chronic conditions. METHODS: Data from the 2005-2009 MarketScan Commercial 
Claims and Encounters databases were used to evaluate prescription fills across 
10 categories of medications. The date of first fill served as the index date for 
each subject and patterns of use were analyzed for at least seven continuous 
calendar quarters within the study window. Cost sharing, expressed as a price 
index for each medication class, was the main explanatory variable to examine 
price elasticity of demand. This index was based on the average cost-sharing 
amount per prescription and was weighted using the national proportion of 
generic and brand medication within each drug category. Negative binomial 
generalized estimating equations models were constructed to examine 
medication fills; standard demographic variables were used to control for 
confounding. RESULTS: Prescription fills per enrollee ranged from 0.01 (smoking 
deterrents) to 0.23 (Statins) and the average spending for medications showed 
considerable variability: those taking thyroid hormone reported an average 
expenditure of $31.29 while those on antiplatelets had an average expenditure of 
$330.38. Additionally, the share of generic drug use within each category ranged 
from 4.7% (smoking deterrents) to 88.4% (NSAIDs/Opioids). Estimates from the 
negative binomial models revealed that the price elasticity of demand ranged 
from -0.015 to -0.157 within the 10 categories of medications (p<0.05 for 9 of 10 
categories). Demand for smoking deterrents proved to be the most price elastic 
of drug categories (-0.157), while NSAIDs/Opioids were observed to be relatively 
price inelastic (-0.015). CONCLUSIONS: The price elasticity of demand varied 
considerably by medication category, suggesting that the influence of cost-
sharing on medication use may be related to characteristics inherent to each 
medication class or underlying condition.  
 
PHP5  
AN ANALYSIS OF THE RELATIONSHIP BETWEEN GROWTH IN PATIENT COST 
SHARING DUE TO BENEFIT DESIGN SHIFTS AND DIAGNOSTIC PRICING AND 
SPENDING  
Abraham J, Garfield S, Sulham K 
GfK Bridgehead, Wayland, MA, USA  
OBJECTIVES: Consumers are shouldering an increasing percentage of health care 
expenditures through cost-sharing mechanisms embedded in benefit design 
structures. As a result, many patients are paying out-of-pocket for some or all of 
the costs associated with diagnostic testing. Traditionally, diagnostic companies 
have focused on demonstrating value to payers with the goal of achieving 
adequate pricing and reimbursement. Though this approach will remain 
necessary, patients are an increasingly critical stakeholder in determining 
whether a diagnostic’s value supports the resulting out-of-pocket costs. This 
study examined how out-of-pocket expenditures by individuals, national health 
expenditures (NHE) on diagnostics, and the price index for diagnostics grew 
between 2005 and 2011. METHODS: A systematic review of published literature 
related to health care expenditure, health insurance coverage, diagnostic pricing, 
and benefit design was performed. In follow-up, data from the Centers for 
Disease Control and Prevention, Bureau of Labor Statistics, Employer Benefits 
Health Survey, and diagnostic industry reports were reviewed to examine growth 
rates over the study period. Basic statistical methods were employed to 
determine how average annual growth rates within each segment relate to other 
variables being considered. RESULTS: The proportion of individuals in America 
with high-deductible health plans has increased 475% in the last six years. This 
correlates to over 25 million Americans responsible for at least $2000 in 
deductible costs in addition to coinsurance and co-pays. During this period, 
pricing of diagnostics only rose at an average annual rate of 1.0%. Overall 
spending on health care increased while diagnostics expenditure remained 
consistent at 6% of NHE. CONCLUSIONS: As health care continues to transform, 
the demand for high quality diagnostics will continue to grow. However, the 
increasing financial burden borne by individuals will lead to increased price 
sensitivity. Novel technologies will need to demonstrate value and clinical utility 
not only to payers, but to patients, to achieve pricing and reimbursement.  
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OBJECTIVES: Racial disparity in duration of patients’ visits to emergency 
departments (EDs) have not been well documented. This study explores the 
racial disparity in duration of routine visits to EDs at teaching and non-teaching 
hospitals. METHODS: Retrospective data analyses and multivariate regression 
analyses were performed to investigate the racial disparity in duration of routine 
ED visits at teaching and non-teaching hospitals. Duration for each visit was 
computed by taking the difference between admission and discharge times. The 
Healthcare Cost and Utilization Project (HCUP) State Emergency Department 
Databases (SEDD) were used in the analyses. The data include 4.3 million routine 
ED visits encountered in Arizona, Massachusetts, and Utah during 2008. SEDD 
provide detailed diagnoses, procedures, total charges, patient demographics, and 
admission and discharge time for each visit. We linked SEDD files with American 
Hospital Association Annual Survey Database, Trauma Information Exchange 
Program Database and Area Resource File to obtain hospital and area level 
characteristics. RESULTS: The mean duration for a routine ED visit was 238 
